Can Targeting Nicotinic Receptors be a Therapeutic Strategy?
Given their role in cancer progression, nicotinic receptors represent a potential target for cancer therapy. Inhibitors of nicotinic receptors, such as α7nAChR antagonists, have shown promise in preclinical studies. These inhibitors can reduce tumor growth and metastasis by blocking the signaling pathways activated by nicotinic receptors. However, more research is needed to develop effective and selective nicotinic receptor inhibitors for clinical use.
